Once worth NIS 1 billion, Pluri is now racing to avoid Nasdaq delisting...

Pluri, an Israeli stem-cell company, was once valued at NIS 1 billion but now faces potential Nasdaq delisting after years of missed commercial targets.

The firm is pursuing a revised strategy focused on the longevity sector in an effort to stabilize its position.